Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

ProQR Therapeutics N.V. diskutieren

ProQR Therapeutics N.V.

WKN: A12B97 / Symbol: PRQR / Name: ProQR / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

1,89 €
3,52 %

Einschätzung Buy
Rendite (%) 45,54 %
Kursziel 4,55
Veränderung
Endet am 07.08.24

ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

Einschätzung Buy
Rendite (%) 49,45 %
Kursziel 3,75
Veränderung
Endet am 08.11.24

ProQR Therapeutics (NASDAQ: PRQR) had its price target lowered by analysts at Raymond James from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for PRQR provided by MarketBeat

Einschätzung Buy
Rendite (%) 49,45 %
Kursziel 1,87
Veränderung
Endet am 08.11.24

ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PRQR provided by MarketBeat

ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PRQR provided by MarketBeat

Einschätzung Buy
Rendite (%) 6,29 %
Kursziel 1,88
Veränderung
Endet am 19.04.25

ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Ratings data for PRQR provided by MarketBeat

Der Beitrag wird untersucht